InvestorsHub Logo
Followers 3
Posts 268
Boards Moderated 0
Alias Born 12/07/2013

Re: None

Sunday, 12/13/2020 4:42:49 PM

Sunday, December 13, 2020 4:42:49 PM

Post# of 17446
HEPA is another company to keep an eye on, if for no other reason than their lead molecule CRV431 is VOC's cousin. They are trialing it in NASH associated liver fibrosis. Low dose phase 2a data expected before EOY, they are expecting to move into higher dose with hope of efficacy in 2021.

They just did a substantial secondary offering at $1.50. CEO was founder of Isotechnika.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News